Compare · ABBV vs KVSA
ABBV vs KVSA
Side-by-side comparison of AbbVie Inc. (ABBV) and Khosla Ventures Acquisition Co. (KVSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and KVSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $433.04B, about 1100.3x KVSA ($393.6M).
- ABBV has hit the wire 12 times in the past 4 weeks while KVSA has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 0 for KVSA).
- Company
- AbbVie Inc.
- Khosla Ventures Acquisition Co.
- Price
- $244.70-0.16%
- $10.73+2.68%
- Market cap
- $433.04B
- $393.6M
- 1M return
- -3.95%
- -
- 1Y return
- +24.11%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2021
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Khosla Ventures Acquisition Co.
Khosla Ventures Acquisition Co. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2021 and is based in Menlo Park, California.
Latest ABBV
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- SEC Form 424B5 filed by AbbVie Inc.
- Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
- UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment
- SEC Form 10-Q filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Second-Quarter 2026 Financial Results
- JUVÉDERM® Day Returns to U.S. on August 19
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Latest KVSA
- SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)
- SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)
- SEC Form 15-12G filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Reports Redemption Of Public Shares And Subsequent Dissolution
- Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution
- OpenAI Investor Vinod Khosla Works 80 Hours A Week, Will Use Peter Thiel's Anti-Aging Methods If They Work
- SEC Form 10-Q filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Co. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing